close

Bharat Biotech starts voluntary recall of rabies vaccine after batch theft

Company had tested the batch and released it, but part of it was stolen, for which cold chain storage integrity was unknown. Decision made to recall the entire batch

Sohini Das Mumbai
Bharat Biotech, vaccine
Premium

Photo: Shutterstock

Hyderabad-based vaccine maker Bharat Biotech on Monday said it has initiated a voluntary recall for a batch of its anti-rabies vaccine Chirorab.
"We have issued a voluntary product recall of a specific batch of Chirorab with batch number 4188. This action was initiated due to the theft of Chirorab from the shipping services provider in Karnataka," the company said in a statement. It added that the company had tested batch No. 4188 and released it, but part of the shipment was stolen, for which cold chain storage conditions are unknown. The action to recall the entire batch has been initiated.
"We are undertaking this voluntary action in accordance with the Principle of Abundant Precaution, keeping patient safety and the public interest in mind," it said.
Or

Also Read

HUL, GSK Asia to scrap distribution pact for OTC products by next year

India's first Covid cure Vincov-19 completes second phase clinical trial

Biotech firm Bharat Serums & Vaccines working to reduce import dependence

Nasal vaccines for Covid-19: How do they work and what are their benefits?

Bharat Biotech says Phase 3 trial over, intranasal vaccine 'safe'

Women's IPL teams auction: BCCI set for another Rs 4,000 crore windfall

Pine Labs acquires enterprise platform from Saluto Wellness for unknown sum

Trade body calls for cheaper land rates to set up industries in Rajasthan

Coal India arm MCL to set up Rs 12,000-crore power plant in Odisha

TaMo, ICICI Bank tie up to offer financing solutions to its EV dealers

First Published: Jan 23 2023 | 7:21 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers. Already a BS Premium subscriber?LOGIN NOW

Register to read more on Business-Standard.com